Non sedating tricyclic antidepressants
The therapeutic daily dosage of trazodone for depression therapy is 150–600 mg/day.
Doses below this level may provide sedative effects but are not expected to combat the symptoms of depression.
Almost 80% of the survey respondents indicated that they would prescribe trazodone to address selective serotonin reuptake inhibitor (SSRI)-induced insomnia.
In light of the common use of trazodone as adjunctive insomnia therapy in depressed patients, it is important to remember that several treatment approaches are available.
Antidepressants used for the treatment of insomnia were the only drug category showing signs of growth—tripling in drug mentions over this period.
The treatment of comorbid depression and insomnia can be achieved through the use of a sedating antidepressant, a combination of two antidepressants, or a combination of an antidepressant in conjunction with a hypnotic. Psychotropic medication and priapism: a comprehensive review. Between 19, the pharmacologic treatment of insomnia decreased markedly. A case of trazodone-induced ventricular tachycardia. A recent review50% for hypnotics, and were down approximately 25% for all forms of insomnia pharmacotherapy combined. This analysis is consistent with a more recent survey of psychiatrists’ prescribing practices. The survey was conducted at a psychopharmacology review course to investigate the management of antidepressant-induced side effects. Mirtazapine: a review of its use in major depression.